Green Highlander

T-Scan Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation T cell receptor (TCR) engineered T cell therapies for the treatment of cancer. The company utilizes its proprietary T-Scan platform to identify naturally occurring TCRs and their associated targets from patients with exceptional anti-tumor responses. Its pipeline includes programs targeting solid tumors and hematologic malignancies, with a focus on overcoming tumor heterogeneity through multi-target "receptor banks." T-Scan aims to provide personalized, off-the-shelf cell therapies that can be tailored to a patient's specific HLA type and tumor antigen profile. The company's lead programs, TSC-100 and TSC-101, are currently in Phase 1 clinical trials for patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation.